**Name of journal: World Journal of Clinical Oncology**

**ESPS Manuscript NO: 9473**

**Columns: Review**

Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions

MilaniA *et al*. Overcoming endocrine resistance in metastatic breast cancer

Andrea Milani, Elena Geuna, Gloria Mittica, Giorgio Valabrega

**Andrea Milani, Elena Geuna, Gloria Mittica, and Giorgio Valabrega,**Institute for Cancer Research and Treatment at Candiolo, University of Torino Medical School, FPO (Fondazione del Piemonte per l’Oncologia), 10060 Candiolo, Italy

**Andrea Milani, Elena Geuna, Gloria Mittica, and Giorgio Valabrega,** Department of Oncology, University of Torino Medical School, 10123 Torino, Italy

**Author contributions:** Milani A ans Geuna E contributed equally to this work; Milani A and Geuna E conceived and wrote the manuscript; Mittica G helped perform the literature search and contributed to writing, revising, and editing the manuscript; Valabrega G supervised the work and contributed to writing, revising, and editing the manuscript.

**Correspondence to: Giorgio Valabrega, MD,** Institute for Cancer Research at Candiolo, University of Torino Medical School, FPO (Fondazione del Piemonte per l’Oncologia), SP 142, Km. 3.95, 10060 Candiolo, Italy. giorgio.valabrega@ircc.it

**Telephone:** +39-01-19933283 **Fax:** +39-01-19933299

**Received:** February 13, 2014  **Revised:** April 4, 2014

**Accepted:** July 18, 2014

**Published online:**

**Abstract**

**About 75% of all breast cancers are estrogen receptor (ER)-positive. They generally have a more favorable** clinical behavior, prognosis, and pattern of recurrence, **and endocrine therapy forms the backbone of treatment.** Anti-estrogens (such as tamoxifen and fulvestrant) and aromatase inhibitors (such as anastrozole, letrozole, and exemestane) can effectively control the disease and induce tumor responses in a large proportion of patients. However, the majority of patients progress during endocrine therapy (acquired resistance) and a proportion of patients may fail to respond to initial therapy (*de novo* resistance). Endocrine resistance is therefore of clinical concern and there is great interest in strategies that delay or circumvent it. A **deeper knowledge of the molecular mechanisms that drive endocrine resistance has recently led to development of new strategies that have the promise to effectively overcome it.** Many resistance mechanisms have been described, and the crosstalk between ER and growth factor receptor signaling pathways seems to represent one of the most relevant. Compounds that are able to inhibit key elements of these pathways and restore endocrine sensitivity have been studied and more are currently under development. The aim of this review is to summarize the molecular pathophysiology of endocrine resistance in breast cancer and its impact on current clinical management.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Everolimus; Mammalian target of rapamycin; PI3K inhibitors; Estrogen receptor; Endocrine resistance

**Core tip: Endocrine therapy forms the backbone of treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC) patients. Unfortunately, resistance to endocrine agents develops in the majority of patients. A deeper knowledge of the molecular mechanisms that drive endocrine resistance has boosted the development of strategies designed to overcome resistance to endocrine therapies. In particular, co-targeting of receptor tyrosine kinase and intracellular signaling pathways (such as the PI3K-Akt-mTOR pathway) has emerged as a particularly promising strategy. We predict that the development of new drugs with a strong underlying biological rationale** will quickly result in more personalized treatment of patients with HR-positive MBC and further improve outcomes.

Milani A, Geuna E, Mittica G, ValabregaG. Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. *World J Clin Oncol* 2014; In press

# INTRODUCTION

Breast cancer is a leading cause of female death worldwide[[1](#_ENREF_1)]. There has been a continuous decline in mortality over recent years as a direct result of improvements in early diagnosis and increased availability of more effective treatments[[2](#_ENREF_2), [3](#_ENREF_3)]. However, despite these improvements, metastatic breast cancer (MBC) remains a largely incurable disease and new treatments need to prolong survival, relieve symptoms, and delay progression.

Approximately 75% of breast cancers express either or both the estrogen receptor (ER) and progesterone receptor (PgR)[[4](#_ENREF_4)]. Hormone receptor (HR)-positive and negative disease differ in terms of clinical behavior, prognosis, patterns of recurrence, and aggressiveness. Patients with HR-positive disease are likely to have more indolent disease, bone metastases, and late recurrences[[5](#_ENREF_5)]. For most HR-positive MBC patients, endocrine therapy is the preferential initial treatment and has a positive impact on survival.

Recently, a number of compounds with different mechanisms of action, low toxicity, and superior efficacy have become available for patients with HR-positive disease. Three classes of endocrine therapies are commonly used to treat HR-positive MBC: selective estrogen receptor modifiers (SERMs), such as tamoxifen, which directly bind to the ER and block its transcriptional activity; selective estrogen receptor downregulators (SERDs), such as fulvestrant, which bind to ER and induce its degradation; and aromatase inhibitors (AIs), such as letrozole, anastrozole, and exemestane, which reduce the production of estrogen via inhibition of the aromatase enzyme in peripheral tissues and within the tumor itself[[6](#_ENREF_6)].

Unfortunately, although long-term remission is possible[[7](#_ENREF_7)], the majority of patients develop resistance to endocrine therapy[[8](#_ENREF_8)]. Moreover, a proportion of patients may have primary resistance to endocrine therapy[[9](#_ENREF_9)]. There is therefore a lot of interest in developing strategies that delay the onset of endocrine resistance or circumvent acquired resistance to specific drugs.

It has recently been suggested that dysregulation of growth factor signaling networks and crosstalk between overexpressed growth factor receptors and ER play an important role in the endocrine-resistant phenotype[[10](#_ENREF_10)]. Manipulating these networks is an attractive and potentially effective strategy that aims to delay the onset, or eventually overcome, resistance to endocrine therapies.

The aims of this review are to provide an overview of the known mechanisms of resistance to endocrine therapies and to focus on emerging strategies aimed at circumventing its development.

# THE BIOLOGY OF THE ER

The ER is mainly a nuclear protein that modulates gene expression via several different pathways. A schematic of the biology of ER signaling is presented in Figure 1.

## *The “classical” pathway*

Estrogen is a steroidal hormone that passively diffuses through cell membranes to enter the cell. The “classical” ER pathway is initiated by estrogen-induced dimerization of ER and subsequent binding to specific DNA promoter regions, known as estrogen response elements (EREs), which activates transcription of genes involved in promoting cellular proliferation and survival[[11](#_ENREF_11)]. ER can also inhibit gene expression, particularly those involved in downregulation of the cell cycle or pro-apoptotic actions. The transcriptional activity of ER is regulated by a number of co-activators (for example, members of the p160 family of nuclear receptor co-activators such as SRC1 and SRC2) that bind to ER to form large complexes[[12](#_ENREF_12), [13](#_ENREF_13)]. In breast cancer cells, SERMs such as tamoxifen lead to the formation of ER-co-repressor complexes that inhibit ER-dependent transcriptional activity to induce anti-proliferative and pro-apoptotic effects.

## *The “non-classical” pathway*

In addition to the “classical” regulation of gene expression, ER also regulates genes that do not harbor EREs in their promoter regions in a “non-classical” manner. ER can, in fact, interact with other proteins that are known to be involved in promoting gene expression, such as Fos and Jun[[14](#_ENREF_14)].

## *Non-nuclear activities of the ER*

Although the majority of cellular ER localizes in the nucleus, the ER can also localize in the cytoplasm and cell membrane, where it can interacts with receptor tyrosine kinase (RTK) growth factor receptors, such as the epidermal growth factor receptor (EGFR), human epidermal growth factor receptor-2 (HER2), or insulin-like growth factor-1 receptor (IGF-1R)[[15](#_ENREF_15)]. In fact, the ER plays a key role in this complex intracellular signaling network and is strictly linked to other signaling networks[[16](#_ENREF_16)]. A complex network of bi-directional crosstalk exists at multiple levels in breast cancer cells, whereby the ER pathway and growth factor receptor signaling pathways interact and potentiate one another, resulting in dysregulated proliferation and growth[[12](#_ENREF_12)].

Therefore, through direct DNA binding, co-activation, or molecular crosstalk, ER can influence tumor cell proliferation, survival, and malignant progression by amplifying the intracellular proliferative signals from RTKs and their downstream effectors.

## *Putative mechanisms of endocrine resistance*

There is strong evidence that crosstalk between growth factor receptor and ER pathways can mediate resistance to endocrine therapy. The ER exists as part of a highly complex and adaptive signaling network that enables cancer cells to escape simple perturbations, such as those presented by the currently available endocrine therapies.

For example, overexpression of members of the EGFR family of RTKs, particularly HER2, has been described as a molecular alteration that is able to confer *de novo* resistance to anti-estrogens[[12](#_ENREF_12)]. HER2 directly phosphorylates ER and its co-regulators, leading to enhanced ligand-independent gene expression, even in the presence of negative regulators such as SERMs.

There are data to suggest that patients with early breast cancers that overexpress HER2 obtain less benefit from adjuvant tamoxifen than those with HER2-negative tumors; furthermore, HER2 overexpression seems to be predictive of a poor clinical response to tamoxifen[[17](#_ENREF_17), [18](#_ENREF_18)]. EGFR overexpression is also predictive of decreased benefit from tamoxifen[[19](#_ENREF_19), [20](#_ENREF_20)] and increased risk of disease progression during anti-estrogen treatment[[21](#_ENREF_21)].

There is emerging evidence to suggest that long-term estrogen deprivation can directly induce the transcription of growth factor receptors such as EGFR, HER2, and IGF-1R, resulting in increased activity of their downstream mediators and increased cellular proliferation, the final result being escape from estrogen deprivation and ligand-autonomous growth[[22-24](#_ENREF_22)].

Another interaction that seems to be crucial in mediating resistance to endocrine therapies involves the phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway, an ubiquitous signal transduction pathway that is also interconnected with other RTKs, including, but not limited to, the EGFR family (Figure 1)[[25-27](#_ENREF_25)]. This pathway regulates many cellular functions, not least growth and proliferation, differentiation, metabolism, migration, and survival[[28](#_ENREF_28)], and it is abnormally activated in many different cancer types, including breast cancer, in which it has an important role in the development of anti-cancer drug resistance.

Dysregulation of this pathway is crucial in the development of acquired endocrine resistance. The pathway can become activated via increased upstream signaling due to activation of RTKs, PI3K-activating mutations, or decreased expression of negative regulators of the pathway, such as through loss of the tumor suppressor PTEN (phosphatase and tensin homolog). For example, several studies have established a link between upregulated Akt protein expression and/or phosphorylation and resistance to endocrine therapy[[29](#_ENREF_29), [30](#_ENREF_30)], and it is known that an mTOR subunit phosphorylates and activates the functional domain 1 of the ER[[31](#_ENREF_31), [32](#_ENREF_32)].

In a preclinical study, deGraffenried *et al*[[33](#_ENREF_33)] reported that breast cancer cells with high Akt activity are resistant to hormonal therapy but that sensitivity could be restored with the use of mTOR inhibitors. Furthermore, in another study of ER-positive breast cancer cells, a combination of mTOR inhibitor and letrozole acted synergistically to inhibit proliferation and trigger apoptosis[[34](#_ENREF_34)].

However, several other mechanisms have been described that contribute to endocrine resistance. For example, loss of ER expression in the evolution from primary to metastatic disease may contribute to the emergence of estrogen resistance; data from clinical studies suggest that 17% of ER-positive patients treated with adjuvant tamoxifen may convert to an ER-negative phenotype at the time of relapse[[35](#_ENREF_35)].

Mutations in *ESR1,* the gene encoding ER, also seem to negatively affect responses to hormonal therapy[[36](#_ENREF_36), [37](#_ENREF_37)]. Recently Toy *et al*[[36](#_ENREF_36)] reported frequent mutations in *ESR1* that affect the ligand-binding domain (LBD) of ER in metastatic hormone-resistant breast cancers after prolonged exposure to hormonal therapy. These highly recurrent mutations mainly affected p.Tyr537Ser, p.Tyr537Asn, and p.Asp538Gly, and as a consequence caused an agonist conformation of the receptor. In addition, they noted that LBD-mutant receptors have a hormone-independent active state that is likely to promote resistance to estrogen-depriving therapies. Interestingly, mutant ER retains some sensitivity to drugs that directly target the receptor, suggesting that more potent ER antagonists may be of substantial therapeutic benefit in this subgroup of individuals.

There may also be individual biological variability in drug metabolism that might influence responses to therapy. For example, about 8% of Caucasian women fail to convert tamoxifen to its active metabolite, endoxifen, which has been suggested to be a mechanism of *de novo* resistance[[38](#_ENREF_38)].

In summary, multiple complex and adaptive mechanisms contribute to the development of endocrine resistance (Figure 1). As our understanding of the mechanisms that underpin resistance improves, the goal of future studies is to prolong responses to endocrine manipulation and potentially restore endocrine sensitivity in those tumors that have become resistant, with or without drugs that target interconnected pathways. Based on this theory, we describe three different approaches to overcome endocrine resistance that have recently been explored clinically in randomized trials.

# OVERCOMING ENDOCRINE RESISTANCE

## *Combined inhibition of the ER and RTKs*

### Combined inhibition with ER- and HER2-targeting agents: HER2 is amplified and/or overexpressed (positive) in around 15 to 20% of human breast cancers. Although overexpression of HER2 is a marker of aggressiveness and poor prognosis, HER2-positive cells are sensitive to anti-HER2 targeted therapy, such as trastuzumab[[39](#_ENREF_39), [40](#_ENREF_40)]. About half of HER2-positive breast cancers co-express hormone receptors and this is associated with resistance to both tamoxifen and AIs, as shown in a number of pre-clinical and clinical studies[[25](#_ENREF_25)]. As a result of this pre-clinical evidence, several trials have explored using a combination of endocrine and HER2-targeting agents to overcome endocrine resistance.

Specifically, three trials have been published to date. The ‘Trastuzumab and Anastrozole Directed Against ER-Positive HER2-Positive Mammary Carcinoma’ (TanDEM) phase 3 study compared anastrozole alone with the combination of anastrozole and trastuzumab as first-line treatment for patients with HER2/HR-positive advanced breast cancer[[41](#_ENREF_41)]. The results showed that the combination of trastuzumab and anastrozole doubled median progression free survival (PFS) (2.4 mo *vs* 4.8 mo) and significantly increased the overall response rate (ORR) (6.8% *vs* 20.3%), compared to anastrozole alone. Side effects were modest and manageable (maximum grade 2) and consisted mainly of fatigue, vomiting, diarrhea, pyrexia, and arthralgia. There was no statistically significant treatment difference in overall survival; however, this may have been due to 70% of patients in the anastrozole arm crossing over to receive trastuzumab after progression on anastrozole alone.

The “Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast” (eLEcTRA) study prematurely closed due to slow recruitment. The design was the same as TanDEM but a different AI (letrozole) was prescribed[[42](#_ENREF_42)]. Similar to TanDEM, eLEcTRA showed that the addition of trastuzumab to letrozole was associated with improved PFS and clinical benefit rate (CBR) at the cost of a modest increase in overall toxicity.

The third study was “EGF30008”, a large, phase 3, double-blind, randomized-controlled trial conducted in 1286 women with HR-positive breast cancer; they were not selected on the basis of HER2 status (of the 1286 patients enrolled, 219 had HER2-positive tumors)[[43](#_ENREF_43), [44](#_ENREF_44)]. These patients were randomized to daily oral treatment with letrozole (2.5 mg) plus the dual HER1-HER2 tyrosine kinase inhibitor lapatinib (1500 mg) *vs* letrozole (2.5 mg) plus placebo. In the ER-positive/HER2-positive population (*n* = 219), the addition of lapatinib to letrozole resulted in a significantly lower risk of disease progression than with letrozole alone. The PFS was 8.2 mo in the combined arm *vs* 3.0 mo in the placebo arm. The ORR (28% *vs* 15%) and CBR (48% *vs* 29%) were also significantly greater in lapatinib treated women. In contrast to the other two studies, the addition of lapatinib was accompanied by a significant increase in the grade 1 and 2 side effects commonly associated with dual tyrosine kinase inhibition, namely diarrhea (68%) and cutaneous rash (46%). The impact of lapatinib plus letrozole on OS has not been reported. However, based upon a clinically meaningful increase in PFS, the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved lapatinib in combination with an aromatase inhibitor in this setting.

As expected, the HER2-negative patients enrolled in EGF30008 derived no benefit in PFS from the addition of lapatinib to letrozole. Interestingly, however, in the sub-group of “tamoxifen-resistant” patients (*i.e*., those relapsing during or within six months from the completion of adjuvant tamoxifen treatment), the improvement in PFS was similar to HER2-positive patients, suggesting that the disruption of crosstalk between the ER and RTK signaling pathways might restore sensitivity to anti-estrogens.

Recently, Finn *et al*[[45](#_ENREF_45)] showed that weak ER expression is associated with worse outcomes for postmenopausal women with advanced HR-positive disease when treated with letrozole alone compared to a combination with lapatinib. Their data suggest that the population of patients with low quantitative expression of ER within the HER2-negative population may be most likely to benefit from the addition of lapatinib to letrozole, at least in terms of PFS improvement. They hypothesize that this benefit could be related to the anti-EGFR effect of lapatinib.

In conclusion, these three trials suggest that the combination of an anti-HER2 agent and an AI has significant clinical benefit and improves PFS compared to endocrine therapy alone. No significant differences in overall survival (OS) were observed in any of the trials, possibly due to the influence of crossover and/or the number of lines of treatment received after progression. Interestingly, these three trials also confirm that HER2-positive patients have relative endocrine resistance; in fact, women receiving endocrine therapy alone had response rates ranging only from 7% to 15% and median time-to-progression (TTP) ranging from 2.4 to 3.3 mo.

These three trials provide proof-of-concept that HER2-associated endocrine resistance may be reverted by targeting HER2 and that combination therapy represents a therapeutic opportunity for patients with these particular clinicopathological features.

### *Combined inhibition with ER- and EGFR-targeting agents*

As previously discussed, the crosstalk between the ER and EGFR has been reported to be mediate endocrine resistance. Therefore, combination strategies have been evaluated in the clinic[[12](#_ENREF_12), [46](#_ENREF_46)].

Although the clinical and prognostic role of EGFR in breast cancer has yet to be fully characterized and is mainly restricted to “basal-like” tumors, a few randomized trials have explored the effect of combined ER and EGFR targeting in women with MBCs not selected on the basis of EGFR status[[47](#_ENREF_47)].

NCT00229697 was a randomized phase II trial that evaluated the addition of the pure EGFR inhibitor gefitinib to tamoxifen in patients with HR-positive advanced breast cancer[[48](#_ENREF_48)]. Patients with newly metastatic disease, or who had recurred after adjuvant tamoxifen, during/after adjuvant AI, or after first-line AI, were randomized to receive tamoxifen plus placebo or tamoxifen plus gefitinib. A trend towards benefit from the combination therapy was seen in patients with tamoxifen-sensitive disease, with an increase in median PFS from 8.8 to 10.9 mo. In the AI-resistant population, no improvement in outcome was observed.

Another randomized phase II trial (NCT00077025), presented by Cristofanilli and colleagues, evaluated the efficacy and tolerability of anastrozole combined with gefitinib or anastrozole with placebo in tamoxifen-resistant women with HR–positive MBC[[49](#_ENREF_49)]. Unfortunately, this study was closed prematurely due to slow accrual, but the data that were gathered showed that PFS was longer in patients receiving the combination therapy than for those patients receiving anastrozole plus placebo (14.7 mo *vs* 8.4 mo).

Both of these studies suggest that the observed benefit of EGFR inhibition can be explained by EGFR activation as a mechanism of adaptation to tamoxifen inhibition. It would be therefore interesting to explore this association in an EGFR overexpressing population, like in the neoadjuvant study published by Polychronis *et al*[[50](#_ENREF_50)]. In this study, both the combination of anastrozole and gefitinib and, interestingly, gefitinib alone showed clinical activity. Although the ORR was similar in both arms, patients assigned to gefitinib and anastrozole had a greater decrease in tumor proliferation (as measured by Ki67 labeling), than those assigned gefitinib and placebo.

## *Combined inhibition of the ER and PI3K-Akt-mTOR signaling*

Crosstalk between the ER signaling pathway and the PI3K-Akt-mTOR signaling pathway is thought to play a crucial role in the development of resistance to endocrine therapy (Figure 2). Specifically, PI3K-Akt-mTOR pathway upregulation is associated with ligand-independent activation of ER and an associated increase in expression of genes regulated by ER, albeit in the presence of anti-estrogens[[30](#_ENREF_30)]. Moreover, several studies have shown that this effect can be reverted using mTOR inhibitors, such as everolimus or temsirolimus[[33](#_ENREF_33), [34](#_ENREF_34)].

These data provide a strong rationale for combining agents that target this pathway and anti-estrogens in an attempt to restore endocrine sensitivity. Based on this, we present a series of clinical studies below that explore the efficacy of this approach.

### *Everolimus*

Everolimus, the 40-O-(2-hydroxyethyl) derivative of sirolimus (a rapamycin analogue), is an oral mTOR inhibitor that binds with high affinity to its intracellular receptor FKBP12, a protein belonging to the immunophilin family. The everolimus-FKBP12 complex interacts with mTOR to inhibit downstream signaling[[51](#_ENREF_51)].

In the phase II trial ‘TAMRAD’, Bachelot *et al*[[53](#_ENREF_53)] evaluated the efficacy and safety of everolimus in combination with tamoxifen in 111 patients with MBC who had relapsed after first line treatment with AIs. 54 patients were randomized to receive everolimus 10 mg/d and tamoxifen 20 mg/d, and the remainder received tamoxifen alone. Patients were stratified in two sub-groups: those who progressed during or within six months after the end of treatment with adjuvant AIs or progressed during the first six months of AIs with metastatic disease were defined having *ex novo* or primary resistance, whereas those who relapsed six or more months after completion of adjuvant AIs or after the first six months of therapy with AIs with metastatic disease were defined having acquired resistance.

The CBR was higher in patients treated with everolimus (61% *vs* 42%; *P =* 0.045) and TTP was longer in the combination arm (8.6 months *vs* 4.5 months; HR 0.54; 95%CI: 0.36–0.81). The subgroup analysis showed that the benefit of the combination therapy was greater in patients with acquired resistance (74% in the secondary resistance subgroup *vs* 46% in the primary resistance subgroup).

Baselga *et al*[[54](#_ENREF_54)]explored the activity of this combination in the neoadjuvant setting. In a phase II trial, 270 postmenopausal patients with ER-positive breast cancer were randomized to receive letrozole 2.5 mg/d plus everolimus 10 mg/d or letrozole 2.5 mg/d plus placebo for 16 weeks prior to surgery. The primary endpoint was clinical response. The clinical response rates were 68.1% *vs* 59.1% in the combination and placebo arms, respectively (*P =* 0.062). Moreover, everolimus showed greater anti-proliferative activity (57% *vs* 30% in the everolimus and placebo arm, respectively; *P <* 0.01), defined as the reduction in cell proliferation assessed in pre- and post-surgical biopsy specimens.

Following these phase II results, a larger randomized, double-blind, phase III study was conducted by the same group[[55](#_ENREF_55)]. The ‘BOLERO-2’ study enrolled 724 patients with HR-positive advanced breast cancer who had recurred or progressed after previous therapy with a non-steroidal AI (letrozole or anastrozole). Patients were randomized to receive exemestane 25 mg/d plus everolimus 10 mg/d or exemestane 25 mg/d plus placebo. The primary endpoint was PFS and the secondary endpoints were OS, ORR, CBR, safety, and quality of life.

The trial was stopped early because the pre-planned interim analysis showed a better PFS in the combination therapy arm (6.9 mo *vs* 2.8 mo in the combination and exemestane alone arms, respectively; *P <* 0.001) and a 57% reduction of risk of progression (HR = 0.43; 95%CI: 0.35–0.54; *P <* 0.001). These data were confirmed in the final PFS analysis conducted at a median follow-up of 18 months[[56](#_ENREF_56)]. PFS was 7.8 *vs* 3.2 months (HR = 0.45; 95%CI: 0.38–0.54; *P <* 0.001) in the combination and placebo arms, respectively, and the magnitude of benefit was irrespective of clinicopathological characteristics, including previous treatment. The ORRs were 12.6% *vs* 1.7% (*P <* 0.001) in the combination and placebo arms, respectively; the CBR was better in the combination arm (51.3% *vs* 26.4% in the everolimus and placebo arms, respectively; *P <* 0.001). The final OS results are still not available and are awaited with interest.

Although generally well tolerated, all the clinical studies have reported toxicity related to everolimus. Data from BOLERO-2 showed that a greater proportion of patients discontinued treatment in the everolimus arm than in the placebo arm (19% *vs* 4%, respectively) due to adverse events. However, no significant difference in overall quality of life was reported between the two arms[[57](#_ENREF_57)]. The most commonly reported toxicities related to everolimus were stomatitis, fatigue, rash, anorexia, and diarrhea; a less common but life-threating adverse event was non-infectious pneumonia (presenting as an acute deterioration in respiratory function with ground glass or patchy opacities on computed tomography scans), which was reported in about 3% of patients. This non-infectious pneumonia seemed to be immunologically mediated and the clinical management often required immediate drug interruption and high doses of corticosteroids. Other concerning toxicities reported were hyperglycemia, hypercholesterolemia, and hypertriglyceridemia[[58](#_ENREF_58), [59](#_ENREF_59)].

***Temsirolimus***

Temsirolimus is a compound that, similar to everolimus, inhibits the kinase activity of mTOR by complexing with FKBP12. However, it differs from everolimus in its pharmacokinetics and toxicity profile[[60](#_ENREF_60)].

In a randomized phase II study, Carpenter *et al*[[61](#_ENREF_61)] explored the activity and safety of oral temsirolimus with letrozole in heavily pre-treated ER-positive MBC patients. This trial had a three-arm design: one arm received letrozole alone, whereas the other two arms received letrozole plus temsirolimus daily (10 mg) or intermittently (30 mg), respectively. One-year PFS was higher in both combination arms with letrozole alone (69%, 62%, and 48%, respectively).

However, these results were not confirmed in a subsequent larger randomized phase III trial conducted by Chow *et al*[[62](#_ENREF_62)] in heavily pre-treated MBC patients; no improvement in PFS was seen in the investigational arm and the study was stopped early.

Temsirolimus has also been evaluated in AI-naïve patients. In a randomized phase III study, 1112 postmenopausal women with ER-positive locally advanced or metastatic BC with no prior exposure to AIs were randomly assigned to receive letrozole plus oral temsirolimus 30 mg/d for five days every two weeks or placebo with the same schedule[[63](#_ENREF_63)]. The independent data monitoring committee also stopped this trial early at the second predefined interim analysis because the study was deemed unlikely to reach its primary endpoint. The published data showed no difference in PFS (8.9 and 9.0 mo, respectively; P = 0.25) between the groups at a median follow-up of 9.5 mo.

### *PI3K inhibitors*

Alterations in the *PIK3CA* gene are the most common somatic mutations in breast cancer, and both crosstalk between the ER and PI3K pathways and PI3K activation are thought to play a role in endocrine resistance[[64](#_ENREF_64), [65](#_ENREF_65)].

* Specifically, PI3K pathway alterations occur in about 70% of breast cancers and include mutations and/or amplificationsof the genes encoding the PI3K catalytic subunits, p110α (*PIK3CA*) and p110β (*PIK3CB*), the PI3K regulatory subunit p85α (*PIK3R1*), and the PI3K effectors *AKT1*, *AKT2*, and *PDK1*. The loss of lipid phosphatases, such as PTEN and INPP4B (inositol polyphosphate-4-phosphatase type II), can also activate the pathway[[66-69](#_ENREF_66)].

In 2012, the Cancer Genome Atlas Network described that luminal ER+ tumors commonly harbor PI3K mutations, 49% in luminal A and 32% in luminal B[[70](#_ENREF_70)]. Fu *et al*[[71](#_ENREF_71)]have recently shown that activation of RTK signaling induces transcription of growth-related genes and causes decreases in ER levels and activity, leading to an inferior response to endocrine therapy. Co-targeting this pathway with ER and PI3K inhibitors therefore appears to be a promising therapeutic opportunity for patients with ER+ breast cancer. In support of this, Fu *et al*[[71](#_ENREF_71)]found that the combination of tamoxifen with a dual PI3K/mTOR inhibitor (BEZ-235) additively reduces cell growth in different ER-positive HER2-negative breast cancer cell line models[[71](#_ENREF_71), [72](#_ENREF_72)]. Furthermore, Sanchez *et al*[[73](#_ENREF_73)]suggested in pre-clinical testing that fulvestrant may sensitize long-term estrogen deprived ER+ breast cancer cells to the therapeutic effects of PI3K inhibitors, with an associated synergistic increase in apoptosis.

At the most recent San Antonio Breast Cancer Conference, Juric *et al*[[75](#_ENREF_75)]presented results from a phase 1b study of the PI3Kα inhibitor GDC-0032 in combination with fulvestrant in patients with ER+ advanced breast cancer. GDC-0032 was administered to 17 patients at a range of doses (six to nine mg/d) in combination with fulvestrant 500 mg every four weeks (with loading dose of 500mg at day one, 14, and 28). The combination appeared to be well tolerated and had promising preliminary efficacy, with a final recommended dose of six mg per day. No dose limiting toxicities (DLTs) were observed and the main adverse events were gastrointestinal toxicities (anorexia, nausea, and diarrhea), metabolic toxicity (hyperglycemia), and rash. Metabolic partial responses were observed in eight out of 11 patients (73%), including those previously treated with fulvestrant[[75](#_ENREF_75)].

At the same conference, another phase 1 trial reported on BKM120, a novel oral pan-PI3K inhibitor, in combination with fulvestrant in postmenopausal women with ER-positive MBC. Fulvestrant 500 mg IM was administered monthly on day one of each 28-day cycle (following the loading dose) and BKM120 was administered daily on day one to 28 of each cycle. 18 patients have been treated at three doses of BKM (80 and 100 mg/d continuously and 100 mg/d, five days on and two days off). Both BKM120 100mg schedules (continuous or intermittent) with fulvestrant were tolerable without DLTs. Liver toxicity (assessed by ALT) has been reported with BKM120, especially with continuous dosing, and often requires dose reduction but not interruption. The results of this trial were promising, with over 50% clinical benefit, one partial response, and five prolonged disease stabilizations.

Phase III studies of this combination have also been started in the same setting and preliminary information was reported at the 2012 American Society of Clinical Oncology (ASCO) annual meeting. For example, the BELLE (buparlisib breast cancer clinical evaluation) trials are investigating the safety and efficacy of buparlisib (BKM120) with fulvestrant.

BELLE2 is a phase III of BKM120 plus fulvestrant in HR-positive HER2-negative advanced breast cancer that has progressed on or after AI therapy, while BELLE3 is a similar phase III trial in patients with advanced breast cancer previously treated with AIs and refractory to endocrine and mTOR inhibitor combination therapy. The results from these trials will not be available for a few years (NCT01610284 and NCT01633060). BELLE4 is a phase II, randomized, double-blind and placebo-controlled study of BKM120 in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer, with or without PI3K pathway activation. Other combination trials using different PI3K inhibitors are currently recruiting, for example BYL719 with letrozole or fulvestrant, and ongoing trials of PI3K inhibitors combined with endocrine agents are summarized in Table 1.

## *Multiple targeting of ER*

Although the functional crosstalk between different molecular pathways and ER are thought to be the largest contributor to the development of endocrine resistance, many other mechanisms have also been described. For example, cells that express mutated ER circumvent inhibition by tamoxifen or long-term estrogen deprivation, as described above, and due to its peculiar mechanism of action, fulvestrant appears to be more active in these situations. Fulvestrant mediates the down-modulation and accelerated degradation of ER, thereby reducing its activity and it availability to other interacting molecules. Moreover, preclinical data suggest that fulvestrant retains and enhances its antitumor activity in the low estrogen environment, such as in the presence of AIs[[76](#_ENREF_76)]. These data support a strong rationale to explore the activity of combining fulvestrant with AIs.

To this end, three large randomized trials have assessed this approach in postmenopausal women with ER-positive MBC[[77-79](#_ENREF_77)]. Mehta *et al*[[79](#_ENREF_79)] explored the activity of fulvestrant (500 mg loading dose, followed by 250 mg on days 14 and 28 and monthly thereafter) in combination with anastrozole compared to anastrozole alone (1 mg/d in both arms) in the first-line setting in women with MBC previously exposed to AIs and tamoxifen in the adjuvant setting. Overall, the study was positive in terms of its primary endpoint, with a small but statistically significant 1.5-mo increase in median PFS. However, the combination was only beneficial in the tamoxifen-naive population. No differences in ORR and CBR were observed in the two arms of the trial.

In the second study, conducted by Bergh *et al*[[77](#_ENREF_77)], women with HR-positive MBC were randomized to receive the same two treatments as above in the first-line setting. Sensitivity to AIs was defined as either no prior exposure or administration of these drugs in the adjuvant setting and relapse occurring after one year from completion of adjuvant endocrine therapy. This trial failed to show differences between the study arms in the primary endpoint of TTP, or in ORR, CBR, and OS.

In the third study, recently published by Johnston *et al*[[78](#_ENREF_78)], patients with MBC resistant to AIs were randomized to fulvestrant (dose and schedule as above) plus anastrozole (1 mg/d), fulvestrant plus placebo or anastrozole, or to exemestane 25 mg/d. Patients were eligible if they progressed while on AIs after a period of at least 12 months for adjuvant therapy or six months for metastatic disease. This study also reported no differences in terms of PFS, OS, ORR, and CBR between the treatment arms.

# CONCLUSIONS AND FUTURE PERSPECTIVES

Endocrine therapy was traditionally thought to be less effective than chemotherapy for the treatment of women with MBC and was consequently demoted to a secondary role. Recently, our understanding of ER biology has improved and, in parallel, our therapeutic armamentarium has expanded with the development of several classes of compounds with different mechanisms of action. As a result, endocrine therapy is the confirmed leader in the treatment of HR-positive MBC due to greater efficacy and negligible toxicity.

However, most women treated with endocrine therapies develop resistance, and several mechanisms of resistance have been described. In particular, ER appears to be a key player in a complex network of signaling pathways that leads to proliferation and survival of cancer cells. Due to the adaptability of this network, cells can easily escape simple perturbations, such as those presented by the currently available endocrine therapies.

Moreover, these observations have provided the rationale for developing drugs that target other interconnected pathways. Combinations of endocrine agents with or without these drugs have recently been tested in randomized trials, with exciting results.

In this paper, we have described three possible strategies to overcome endocrine resistance, some of which are already becoming part of clinical practice.

Of these, co-targeting the RTK signaling pathways and intracellular signaling networks is the most effective. Lapatinib has recently been approved in patients with HER2- and ER-positive breast cancer, and everolimus has been approved in combination with exemestane for women refractory to AIs. Many other drugs that target intracellular signaling networks, especially the PI3K-mTOR-Akt axis, are currently under development and some of these have shown promising results.

However, recent advances in the understanding of the biology of ER signaling and of the molecular markers of resistance have highlighted that ER and its pathway remain central to endocrine resistance. These findings are likely to translate into new strategies to overcome endocrine resistance in the near future. For example, targeting tumors with specific ER mutations with more potent and specific anti-estrogens seems to be a fascinating approach.

All these advances have positively impacted on survival of women with HR-positive MBC. They chart a course towards the biology-based selection of treatments and a more rational use of chemotherapy to improve efficacy and limit toxicity in women with breast cancer.

**REFERENCES**

1 **Siegel R**, Naishadham D, Jemal A. Cancer statistics, 2013. *CA Cancer J Clin* 2013; **63**: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]

2 **Winkfield KM**, Harris JR. Effective local therapy and long-term survival in breast cancer. *Oncology (Williston Park)* 2009; **23**: 669-675 [PMID: 19711579]

3 **Cady B**, Michaelson JS, Chung MA. The "tipping point" for breast cancer mortality decline has resulted from size reductions due to mammographic screening. *Ann Surg Oncol* 2011; **18**: 903-906 [PMID: 21267787 DOI: 10.1245/s10434-011-1557-y]

4 **Lal P**, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. *Am J Clin Pathol* 2005; **123**: 541-546 [PMID: 15743737 DOI: 10.1309/YMJ3-A83T-B39M-RUT9]

5 **Blanco G**, Holli K, Heikkinen M, Kallioniemi OP, Taskinen P. Prognostic factors in recurrent breast cancer: relationships to site of recurrence, disease-free interval, female sex steroid receptors, ploidy and histological malignancy grading. *Br J Cancer* 1990; **62**: 142-146 [PMID: 2390476]

6 **Pietras RJ**. Biologic basis of sequential and combination therapies for hormone-responsive breast cancer. *Oncologist* 2006; **11**: 704-717 [PMID: 16880230 DOI: 10.1634/theoncologist.11-7-704]

7 **Kuss JT**, Muss HB, Hoen H, Case LD. Tamoxifen as initial endocrine therapy for metastatic breast cancer: long term follow-up of two Piedmont Oncology Association (POA) trials. *Breast Cancer Res Treat* 1997; **42**: 265-274 [PMID: 9065610]

8 **Ellis M**. Overcoming endocrine therapy resistance by signal transduction inhibition. *Oncologist* 2004; **9 Suppl 3**: 20-26 [PMID: 15163844]

9 **Kurebayashi J**. Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance. *Breast Cancer* 2003; **10**: 112-119 [PMID: 12736563]

10 **Ghayad SE**, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. *Int J Cancer* 2010; **126**: 545-562 [PMID: 19609946 DOI: 10.1002/ijc.24750]

11 **Osborne CK**, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. *J Clin Oncol* 2005; **23**: 1616-1622 [PMID: 15755967 DOI: 10.1200/JCO.2005.10.036]

12 **Arpino G**, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. *Endocr Rev* 2008; **29**: 217-233 [PMID: 18216219 DOI: 10.1210/er.2006-0045]

13 **Katzenellenbogen BS**, Montano MM, Ediger TR, Sun J, Ekena K, Lazennec G, Martini PG, McInerney EM, Delage-Mourroux R, Weis K, Katzenellenbogen JA. Estrogen receptors: selective ligands, partners, and distinctive pharmacology. *Recent Prog Horm Res* 2000; **55**: 163-93; discussion 194-5 [PMID: 11036937]

14 **Yager JD**, Davidson NE. Estrogen carcinogenesis in breast cancer. *N Engl J Med* 2006; **354**: 270-282 [PMID: 16421368 DOI: 10.1056/NEJMra050776]

15 **Park JH**, Lee MY, Han HJ. A potential role for caveolin-1 in estradiol-17beta-induced proliferation of mouse embryonic stem cells: involvement of Src, PI3K/Akt, and MAPKs pathways. *Int J Biochem Cell Biol* 2009; **41**: 659-665 [PMID: 18694845 DOI: 10.1016/j.biocel.2008.07.010]

16 **Pancholi S**, Lykkesfeldt AE, Hilmi C, Banerjee S, Leary A, Drury S, Johnston S, Dowsett M, Martin LA. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. *Endocr Relat Cancer* 2008; **15**: 985-1002 [PMID: 18824559 DOI: 10.1677/ERC-07-0240]

17 **Dowsett M**, Johnston S, Martin LA, Salter J, Hills M, Detre S, Gutierrez MC, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Smith I. Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. *Endocr Relat Cancer* 2005; **12 Suppl 1**: S113-S117 [PMID: 16113087 DOI: 10.1677/erc.1.01044]

18 **De Laurentiis M**, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. *Clin Cancer Res* 2005; **11**: 4741-4748 [PMID: 16000569 DOI: 10.1158/1078-0432.CCR-04-2569]

19 **Stotter A**, Walker R. Tumour markers predictive of successful treatment of breast cancer with primary endocrine therapy in patients over 70 years old: a prospective study. *Crit Rev Oncol Hematol* 2010; **75**: 249-256 [PMID: 19969469 DOI: 10.1016/j.critrevonc.2009.10.008]

20 **Nicholson RI**, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO, Blamey RW. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. *Eur J Cancer* 1993; **29A**: 1018-1023 [PMID: 8098946]

21 **Arpino G**, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. *Clin Cancer Res* 2004; **10**: 5670-5676 [PMID: 15355892 DOI: 10.1158/1078-0432.CCR-04-0110]

22 **Yarden RI**, Wilson MA, Chrysogelos SA. Estrogen suppression of EGFR expression in breast cancer cells: a possible mechanism to modulate growth. *J Cell Biochem Suppl* 2001; Suppl 36: 232-246 [PMID: 11455588]

23 **Salvatori L**, Pallante P, Ravenna L, Chinzari P, Frati L, Russo MA, Petrangeli E. Oestrogens and selective oestrogen receptor (ER) modulators regulate EGF receptor gene expression through human ER alpha and beta subtypes via an Sp1 site. *Oncogene* 2003; **22**: 4875-4881 [PMID: 12894229 DOI: 10.1038/sj.onc.1206784]

24 **Gutierrez MC**, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Dowsett M. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. *J Clin Oncol* 2005; **23**: 2469-2476 [PMID: 15753463 DOI: 10.1200/JCO.2005.01.172]

25 **Musgrove EA**, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. *Nat Rev Cancer* 2009; **9**: 631-643 [PMID: 19701242 DOI: 10.1038/nrc2713]

26 **Laplante M**, Sabatini DM. mTOR signaling in growth control and disease. *Cell* 2012; **149**: 274-293 [PMID: 22500797 DOI: 10.1016/j.cell.2012.03.017]

27 **Miller TW**, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. *Breast Cancer Res* 2011; **13**: 224 [PMID: 22114931 DOI: 10.1186/bcr3039]

28 **Dillon RL**, White DE, Muller WJ. The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. *Oncogene* 2007; **26**: 1338-1345 [PMID: 17322919 DOI: 10.1038/sj.onc.1210202]

29 **Beeram M**, Tan QT, Tekmal RR, Russell D, Middleton A, DeGraffenried LA. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. *Ann Oncol* 2007; **18**: 1323-1328 [PMID: 17693645]

30 **Schiff R**, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. *Clin Cancer Res* 2004; **10**: 331S-336S [PMID: 14734488]

31 **Miller TW**, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y, Arteaga CL. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. *J Clin Invest* 2010; **120**: 2406-2413 [PMID: 20530877 DOI: 10.1172/JCI41680]

32 **Massarweh S**, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. *Cancer Res* 2008; **68**: 826-833 [PMID: 18245484 DOI: 10.1158/0008-5472.CAN-07-2707]

33 **deGraffenried LA**, Friedrichs WE, Russell DH, Donzis EJ, Middleton AK, Silva JM, Roth RA, Hidalgo M. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. *Clin Cancer Res* 2004; **10**: 8059-8067 [PMID: 15585641]

34 **Boulay A**, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. *Clin Cancer Res* 2005; **11**: 5319-5328 [PMID: 16033851]

35 **Kuukasjärvi T**, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. *J Clin Oncol* 1996; **14**: 2584-2589 [PMID: 8823339]

36 **Toy W**, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. *Nat Genet* 2013; **45**: 1439-1445 [PMID: 24185512 DOI: 10.1038/ng.2822]

37 **Robinson DR**, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L, Gursky A, Siddiqui J, Tomlins SA, Roychowdhury S, Pienta KJ, Kim SY, Roberts JS, Rae JM, Van Poznak CH, Hayes DF, Chugh R, Kunju LP, Talpaz M, Schott AF, Chinnaiyan AM. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. *Nat Genet* 2013; **45**: 1446-1451 [PMID: 24185510 DOI: 10.1038/ng.2823]

38 **Hoskins JM**, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. *Nat Rev Cancer* 2009; **9**: 576-586 [PMID: 19629072 DOI: 10.1038/nrc2683]

39 **Slamon DJ**, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 2001; **344**: 783-792 [PMID: 11248153 DOI: 10.1056/NEJM200103153441101]

40 **Yarden Y**, Sliwkowski MX. Untangling the ErbB signalling network. *Nat Rev Mol Cell Biol* 2001; **2**: 127-137 [PMID: 11252954 DOI: 10.1038/35052073]

41 **Kaufman B**, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Révil C, Jones A. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. *J Clin Oncol* 2009; **27**: 5529-5537 [PMID: 19786670 DOI: 10.1200/JCO.2008.20.6847]

42 **Huober J**, Fasching PA, Barsoum M, Petruzelka L, Wallwiener D, Thomssen C, Reimer T, Paepke S, Azim HA, Ragosch V, Kubista E, Baumgärtner AK, Beckmann MW, May C, Nimmrich I, Harbeck N. Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. *Breast* 2012; **21**: 27-33 [PMID: 21862331 DOI: 10.1016/j.breast.2011.07.006]

43 **Johnston S**, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. *J Clin Oncol* 2009; **27**: 5538-5546 [PMID: 19786658 DOI: 10.1200/JCO.2009.23.3734]

44 **Schwartzberg LS**, Franco SX, Florance A, O'Rourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. *Oncologist* 2010; **15**: 122-129 [PMID: 20156908 DOI: 10.1634/theoncologist.2009-0240]

45 **Finn RS**, Press MF, Dering J, O'Rourke L, Florance A, Ellis C, Martin AM, Johnston S. Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. *Clin Cancer Res* 2014; **20**: 736-743 [PMID: 24198242 DOI: 10.1158/1078-0432.CCR-13-1260]

46 **Arpino G**, De Angelis C, Giuliano M, Giordano A, Falato C, De Laurentiis M, De Placido S. Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. *Oncology* 2009; **77 Suppl 1**: 23-37 [PMID: 20130429 DOI: 10.1159/000258493]

47 **Hoadley KA**, Weigman VJ, Fan C, Sawyer LR, He X, Troester MA, Sartor CI, Rieger-House T, Bernard PS, Carey LA, Perou CM. EGFR associated expression profiles vary with breast tumor subtype. *BMC Genomics* 2007; **8**: 258 [PMID: 17663798 DOI: 10.1186/1471-2164-8-258]

48 **Osborne CK**, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. *Clin Cancer Res* 2011; **17**: 1147-1159 [PMID: 21220480 DOI: 10.1158/1078-0432.CCR-10-1869]

49 **Cristofanilli M**, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. *Clin Cancer Res* 2010; **16**: 1904-1914 [PMID: 20215537 DOI: 10.1158/1078-0432.CCR-09-2282]

50 **Polychronis A**, Sinnett HD, Hadjiminas D, Singhal H, Mansi JL, Shivapatham D, Shousha S, Jiang J, Peston D, Barrett N, Vigushin D, Morrison K, Beresford E, Ali S, Slade MJ, Coombes RC. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. *Lancet Oncol* 2005; **6**: 383-391 [PMID: 15925816 DOI: 10.1016/S1470-2045(05)70176-5]

51 **O'Donnell A**, Faivre S, Burris HA, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. *J Clin Oncol* 2008; **26**: 1588-1595 [PMID: 18332470 DOI: 10.1200/JCO.2007.14.0988]

52 **Awada A**, Cardoso F, Fontaine C, Dirix L, De Grève J, Sotiriou C, Steinseifer J, Wouters C, Tanaka C, Zoellner U, Tang P, Piccart M. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. *Eur J Cancer* 2008; **44**: 84-91 [PMID: 18039566]

53 **Bachelot T**, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. *J Clin Oncol* 2012; **30**: 2718-2724 [PMID: 22565002 DOI: 10.1200/JCO.2011.39.0708]

54 **Baselga J**, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. *J Clin Oncol* 2009; **27**: 2630-2637 [PMID: 19380449 DOI: 10.1200/JCO.2008.18.8391]

55 **Baselga J**, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med* 2012; **366**: 520-529 [PMID: 22149876 DOI: 10.1056/NEJMoa1109653]

56 **Yardley DA**, Noguchi S, Pritchard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. *Adv Ther* 2013; **30**: 870-884 [PMID: 24158787 DOI: 10.1007/s12325-013-0060-1]

57 **Burris HA**, Lebrun F, Rugo HS, Beck JT, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi GN, Komorowski A, Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Ricci JF, Bauly H, Taran T, Sahmoud T, Noguchi S. Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. *Cancer* 2013; **119**: 1908-1915 [PMID: 23504821 DOI: 10.1002/cncr.28010]

58 **Paplomata E**, Zelnak A, O'Regan R. Everolimus: side effect profile and management of toxicities in breast cancer. *Breast Cancer Res Treat* 2013; **140**: 453-462 [PMID: 23907751 DOI: 10.1007/s10549-013-2630-y]

59 **Peterson ME**. Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. *Support Care Cancer* 2013; **21**: 2341-2349 [PMID: 23686401 DOI: 10.1007/s00520-013-1826-3]

60 **Buckner JC**, Forouzesh B, Erlichman C, Hidalgo M, Boni JP, Dukart G, Berkenblit A, Rowinsky EK. Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. *Invest New Drugs* 2010; **28**: 334-342 [PMID: 19415181 DOI: 10.1007/s10637-009-9257-1]

61 **Carpenter JT**, Roche H, Campone M, Colomer R, Jagiello-Gruszfeld A, Moore L, D'Amore M, Kong S, Boni J, Baselga J. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. ASCO Meeting Abstracts 2005; **23**(16\_suppl): 564

62 **Chow L**, Sun Y, Jassem J, Baselga J, Hayes D, Wolff A, Hachemi S, Cincotta M, Yu B, Kong S. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Proceedings of the Breast Cancer Research and Treatment; 2006. SPRINGER 233 SPRING STREET, NEW YORK, NY 10013 USA: S286-S286

63 **Wolff AC**, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, Sun Y, Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P, Chan A, Hachemi S, Strahs A, Cincotta M, Berkenblit A, Krygowski M, Kang LL, Moore L, Hayes DF. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. *J Clin Oncol* 2013; **31**: 195-202 [PMID: 23233719 DOI: 10.1200/JCO.2011.38.3331]

64 **Mills GB**, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. *Semin Oncol* 2003; **30**: 93-104 [PMID: 14613030]

65 **Hennessy BT**, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. *Nat Rev Drug Discov* 2005; **4**: 988-1004 [PMID: 16341064 DOI: 10.1038/nrd1902]

66 **Stemke-Hale K**, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. *Cancer Res* 2008; **68**: 6084-6091 [PMID: 18676830 DOI: 10.1158/0008-5472.CAN-07-6854]

67 **Ellis MJ**, Lin L, Crowder R, Tao Y, Hoog J, Snider J, Davies S, DeSchryver K, Evans DB, Steinseifer J, Bandaru R, Liu W, Gardner H, Semiglazov V, Watson M, Hunt K, Olson J, Baselga J. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. *Breast Cancer Res Treat* 2010; **119**: 379-390 [PMID: 19844788 DOI: 10.1007/s10549-009-0575-y]

68 **Campbell IG**, Russell SE, Choong DY, Montgomery KG, Ciavarella ML, Hooi CS, Cristiano BE, Pearson RB, Phillips WA. Mutation of the PIK3CA gene in ovarian and breast cancer. *Cancer Res* 2004; **64**: 7678-7681 [PMID: 15520168 DOI: 10.1158/0008-5472.CAN-04-2933]

69 **Pérez-Tenorio G**, Alkhori L, Olsson B, Waltersson MA, Nordenskjöld B, Rutqvist LE, Skoog L, Stål O. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. *Clin Cancer Res* 2007; **13**: 3577-3584 [PMID: 17575221 DOI: 10.1158/1078-0432.CCR-06-1609]

70 **Cancer Genome Atlas N**. Comprehensive molecular portraits of human breast tumours. *Nature* 2012; **490**: 61-70 [PMID: 23000897 DOI: 10.1038/nature11412]

71 **Fu X**, Osborne CK, Schiff R. Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. *Breast* 2013; **22** Suppl 2: S12-S18 [PMID: 24011769 DOI: 10.1016/j.breast.2013.08.001]

72 **Creighton CJ**, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. *Breast Cancer Res* 2010; **12**: R40 [PMID: 20569503 DOI: 10.1186/bcr2594]

73 **Sanchez CG**, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. *Breast Cancer Res* 2011; **13**: R21 [PMID: 21362200 DOI: 10.1186/bcr2833]

74 Dixon JM RL, Keys J, Sims A, Thomas J, Wilson TR, Lackner MR. PI3-kinase mutations in recurrences in patients with estrogen receptor positive breast cancer. Abstract San Antonio Breast Cancer Symposia 2013

75 Juric D SC, Cervantes A, Kurkjian C, Patel MR, Sachdev J, Mayer I, Krop IE, Oliveira M, Sanabria S, Cheeti S, Lin RS, Graham RA, Wilson TR, Parmar H, Hsu JY, Von Hoff DD, Baselga J. Ph1b study of the PI3K inhibitor GDC-0032 in combination with fulvestrant in patients with hormone receptor-positive advanced breast cancer. Abstract San Antonio Breast Cancer Symposia 2013


76 **Jelovac D**, Macedo L, Goloubeva OG, Handratta V, Brodie AM. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. *Cancer Res* 2005; **65**: 5439-5444 [PMID: 15958593 DOI: 10.1158/0008-5472.CAN-04-2782]

77 **Bergh J**, Jönsson PE, Lidbrink EK, Trudeau M, Eiermann W, Brattström D, Lindemann JP, Wiklund F, Henriksson R. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. *J Clin Oncol* 2012; **30**: 1919-1925 [PMID: 22370325 DOI: 10.1200/JCO.2011.38.1095]


78 **Johnston SR**, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, Im YH, Braybrooke JP, Brunt AM, Cheung KL, Jyothirmayi R, Robinson A, Wardley AM, Wheatley D, Howell A, Coombes G, Sergenson N, Sin HJ, Folkerd E, Dowsett M, Bliss JM. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial.*Lancet Oncol* 2013; **14**: 989-998 [PMID: 23902874 DOI: 10.1016/S1470-2045(13)70322-X]

79 **Mehta RS**, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Combination anastrozole and fulvestrant in metastatic breast cancer. *N Engl J Med* 2012; **367**: 435-444 [PMID: 22853014 DOI: 10.1056/NEJMoa1201622]

**P-Reviewer:** El SherbiniMAH, Wang SK, Zaniboni A **S-Editor:** Wen LL **L-Editor: E-Editor:**



**Figure 1** **The biology of the estrogen receptor and a schematic representation of the key mechanisms of endocrine resistance.** A: Estrogen induces gene regulation via the “classical” pathway. Estrogen passively diffuses through cell membranes and binds to the estrogen receptor (ER), inducing receptor dimerization. This complex recruits co-activators (CoA) and binds regions of DNA known as estrogen response elements (EREs), promoting transcription. Aromatase inhibitors (AIs) negatively regulate ER activity by reducing circulating estrogen levels; B: The ER can also cooperate with other transcription factors (TFs) and regulate the transcription of genes not harbouring EREs *via* the “non-classical” pathway; C: ER strictly interacts with receptor tyrosine kinases (RTKs) via their downstream effectors. ER can, in fact, be directly phosphorylated and activated, the final result being gene expression and a cascade of second intracellular effectors (the non-nuclear activity of ER); D: This strict and bi-directional crosstalk between ER and RTKs and downstream effectors is responsible for endocrine resistance; E: In breast cancer cells, SERMs [such as tamoxifen (Tam)] bind ER and induce the recruitment of co-repressors (CoR) that negatively regulate the activity of ER. Mutated forms of ER are able to enhance gene expression in spite of the presence of Tam.



**Figure 2 A representation of the molecular crosstalk between estrogen receptor and the receptor tyrosine kinases and PI3K-Akt-mTOR axes.** In breast cancer, the PI3K-Akt-mTOR pathway modulates responses to signals communicated through growth factor receptors and the estrogen receptor (ER), and this crosstalk is important for sensitivity to anti-endocrine therapy. In particular, Akt and ERK1/2 phosphorylate ER on key residues involved in the induction of ligand-independent activation of DNA transcription. Furthermore, the converse occurs: estradiol, bound to membrane ER, interacts with and activates a regulatory subunit of PI3K. The mammalian target of rapamycin (mTOR) signaling cascade is another key regulatory pathway that controls proliferation and survival in cancer cells and plays an important role in the molecular crosstalk with the ER pathway. Two mTOR-interacting proteins, raptor and rictor, define distinct branches of the mTOR pathway: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Both active mTORC1 (via the phosphorylation of downstream targets, such as 4E-BP1 and p70S6 Kinase) and active mTORC2 contribute to promoting cellular survival and proliferation.

EGF: Epidermal growth factor; IGF: Insulin-like growth factor; PDGF: Platelet derived growth factor; PI3K: Phosphatidylinositol-3-phosphate kinase; ER: Estrogen receptor; E2: Estradiol; IRS-1: Insulin receptor substrate-1; RAS–RAF–MEK–ERK: Mitogen activated protein kinase pathway; HSP90: Heat shock protein 90; PDK-1: Pyruvate dehydrogenase lipoamide kinase isozyme 1; p70S6K: Protein 70S6 kinase; 4E-BP1: Eukaryotic translation initiation factor 4E-binding protein 1; ERE: Estrogen response element.

**Table 1 Ongoing clinical trials of PI3K inhibitors in combination with endocrine therapy in hormone receptor-positive metastatic breast cancer**

|  |  |  |  |
| --- | --- | --- | --- |
| **Treatment** | **Disease conditions** | **Trial status** | **Trial number** |
| **Phase I** |  |  |  |
| BYL719+letrozole | Postmenopausal women hormone receptor-positive stage IV breast cancer | Ongoing | NCT01791478 |
| BKM120+fulvestrant | Postmenopausal women estrogen receptor-positive stage IV breast cancer | Ongoing | NCT01339442 |
| BKM120 or BEZ235+letrozole | Postmenopausal women hormone receptor-positive stage IV breast cancer | Ongoing, not recruiting | NCT01248494 |
| XL147 or XL765+letrozole | Postmenopausal women hormone receptor-positive stage IV breast cancer | Completed | NCT01082068 |
| **Phase II** |  |  |  |
| PF-04691502+exemestane *vs* exemestane alone | Estrogen receptor-positive stage IV breast cancer | Withdrawn prior to enrolment | NCT01658176 |
| PF-4691502+letrozole *vs* letrozole alone | Postmenopausal women estrogen receptor-positive early (phase II) and advanced (phase Ib) breast cancer | Terminated | NCT01430585 |
| GDC-0941 or GDC-0980/placebo+fulvestrant | Postmenopausal women estrogen receptor-positive, AI treated, stage IIIB-IV breast cancer | Ongoing | NCT01437566 |
| **Phase III** |  |  |  |
| BKM120/placebo+fulvestrant | Postmenopausal women hormone receptor-positive, AI treated, stage IIIB-IV breast cancer progressed on or after mTOR inhibitor-based treatment | Ongoing | NCT01633060 |
| BKM120/placebo+fulvestrant | Postmenopausal women hormone receptor-positive, stage IIIB-IV breast cancer refractory to AIs | Ongoing | NCT01610284 |